Q2 2024

Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001493152-24-032266

Q2 2024 · 10-Q

Revenue—

Net Income

-$1.61M

N/M vs Q2 2023

EPS Diluted

$0.00

— vs Q2 2023

Operating Income-$1,486,138N/M

Operating Cash Flowderived-$510,776N/M

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	—	—	—	$0.00
Net Income	-$1.61M	-$589.09K	-$1.04M	-$2.75M
EPS Diluted	$0.00	$0.00	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR